Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform the treatment of autoimmune diseases and cancer by developing allogeneic, iPSC-derived cell therapies.
PRESS RELEASES + EVENTS
view all
May 28, 2025
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative…
May 15, 2025
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to…
About us
We are building an industry-leading, allogeneic, iPSC-derived cell therapy platform for autoimmune diseases and cancer.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
